Researchers Develop Novel Gene Therapy for Rare Genetic Disease

Introduction

Hereditary transthyretin amyloidosis (hATTR) is a debilitating genetic disorder caused by mutations in the transthyretin (TTR) gene. This disease leads to the accumulation of misfolded TTR proteins, which form amyloid fibrils that can damage tissues and organs. There is currently no cure for hATTR, but a promising new gene therapy approach has been developed by researchers.

Groundbreaking Advance in Gene Therapy

A team of scientists, led by Dr. Maria Grazia Roncarolo, has made a significant breakthrough in the development of a gene therapy for hATTR. The team has engineered a gene therapy vector that can deliver a functional copy of the TTR gene to the liver, where the TTR protein is produced.

Mechanism of Action

The gene therapy vector is a modified version of a virus called adeno-associated virus (AAV). AAVs are commonly used in gene therapy because they can infect cells without causing disease. Once inside the liver cells, the AAV vector delivers the functional TTR gene, which then instructs the cells to produce normal TTR protein.

Preclinical Studies Show Promise

Preclinical studies in animal models of hATTR have shown that the gene therapy is effective in reducing the production of misfolded TTR and preventing the formation of amyloid fibrils. In these studies, the gene therapy significantly improved the survival and function of animals with hATTR.

Clinical Trial Underway

Based on the promising preclinical results, a clinical trial has been initiated to evaluate the safety and efficacy of the gene therapy in humans with hATTR. The trial is currently enrolling patients at multiple sites worldwide.

Potential Impact

If the gene therapy is successful in clinical trials, it could provide a much-needed treatment option for patients with hATTR. The therapy has the potential to halt or even reverse the progression of the disease, significantly improving the quality of life for patients.

Detailed Description of the Gene Therapy

The gene therapy vector used in this approach is derived from AAV serotype 8. This serotype has been chosen because it has a natural tropism for liver cells. The vector contains a promoter sequence that drives the expression of the TTR gene under the control of a liver-specific regulator.

Manufacturing and Administration

The gene therapy vector is manufactured using a standard process that involves culturing AAVs in a bioreactor. The vector is then purified and concentrated to ensure a high purity and potency. The gene therapy is administered to patients via a single intravenous infusion.

Monitoring and Follow-Up

After administration, patients are closely monitored for safety and efficacy. Blood tests and liver biopsies are used to assess the levels of TTR protein and the presence of amyloid fibrils. Patients are also followed for long-term outcomes, such as survival, organ function, and quality of life.

Conclusion

The development of this gene therapy for hATTR represents a significant advance in the field of rare disease treatment. The promising preclinical results and the ongoing clinical trial raise hope for a potential cure for this devastating disease. If successful, this gene therapy could transform the lives of countless patients with hATTR and their families.

How can Genetic Engineering be used to Treat or Cure Diseases genetic engineering diseases cure gene editing treat used scissors

EMA approves New gene therapy to treat rare genetic disorder genetic disorder ema metachromatic leukodystrophy approves

Jimmy Fund Childhood cancer and the promise of gene therapy

Rare Diseases Making Treatments Less Rare with Gene Therapy

Novel gene therapy platform speeds search for ways to cure blindness

Guangping Gao and Dan Wang partner with ASC Therapeutics to develop gao asc develop urine therapeutics syrup gene phd umassmed

Tessera Raises 0M to Develop 'Gene Writing' into Novel Genetic Therapy gene writing 2021 raises tessera novel develop genetic therapy into comment leave 230m

Premium AI Image Gene therapy for rare genetic diseases with no

sickle cell disease cure Sickle cell disease Diseases Club Center 2

Frontiers Organoids and microphysiological systems Promising models

Different Approaches ASGCT American Society of Gene & Cell Therapy approaches gene therapy cell vs therapeutic different traditional pdf drugs

Toward Clinical Implementation of NextGeneration SequencingBased

Gene Therapy for Adenosine Deaminase Deficiency Immunology and

What is gene therapy? ExtremeTech gene therapy work cystic fibrosis replacement does works genes process syndrome barth genetics not figure do extremetech approaches picture disease

Researchers develop novel therapy for crimeancongo hemorrhagic fever fever congo crimean hemorrhagic develop

Join Avance Biosciences™ at Gene Therapy for Rare Disorders Mar 2023

Two therapies cure rare genetic disease in mice mice genetic disease graphical abstract rare two therapies cure jci insight 1172

Life Free FullText CRISPRBased Tools for Fighting Rare Diseases

Rare Disease > Premier Research rare clinical trials

Gene Therapy for Rare Diseases gene therapy diseases rare

What is Luxturna? Novel gene therapy to treat rare inherited blindness full blindness gene therapy trains ahead steam hope

When might you get Alzheimer's? New gene test may tell Inquirer alzheimer test gene genetic risk disease diagnosis tell might may get inquirer technology alzheimers when researchers assess miami tuesday said

The History of Gene Therapy and How It is Advancing Rare Disease Cures

Gene Therapy for Rare Disorders Becoming More and More Viable gene therapy rare disorders becoming viable

Location:

Share :